5CEI image
Entry Detail
PDB ID:
5CEI
Title:
Crystal structure of CDK8:Cyclin C complex with compound 22
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2015-07-06
Release Date:
2016-02-10
Method Details:
Experimental Method:
Resolution:
2.24 Å
R-Value Free:
0.22
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Cyclin-dependent kinase 8
Chain IDs:A
Chain Length:406
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Cyclin-C
Chain IDs:B
Chain Length:287
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.
Acs Med.Chem.Lett. 7 223 228 (2016)
PMID: 26985305 DOI: 10.1021/acsmedchemlett.5b00278

Abstact

Beginning with promiscuous COT inhibitors, which were found to inhibit CDK8, a series of 6-aza-benzothiophene containing compounds were developed into potent, selective CDK8 inhibitors. When cocrystallized with CDK8 and cyclin C, these compounds exhibit an unusual binding mode, making a single hydrogen bond to the hinge residue A100, a second to K252, and a key cation-π interaction with R356. Structure-based drug design resulted in tool compounds 13 and 32, which are highly potent, kinase selective, permeable compounds with a free fraction >2% and no measurable efflux. Despite these attractive properties, these compounds exhibit weak antiproliferative activity in the HCT-116 colon cancer cell line. Further examination of the activity of 32 in this cell line revealed that the compound reduced phosphorylation of the known CDK8 substrate STAT1 in a manner identical to a CDK8 knockout clone, illustrating the complex effects of inhibition of CDK8 kinase activity in proliferation in these cells.

Legend

Protein

Chemical

Disease

Primary Citation of related structures